Top-Rated StocksTop-RatedNASDAQ:INSM Insmed (INSM) Stock Price, News & Analysis → Move Your Money Before May 1 (From Stansberry Research) (Ad) Free INSM Stock Alerts $24.80 -0.12 (-0.48%) (As of 02:58 PM ET) Add Compare Share Share Today's Range$24.63▼$25.0650-Day Range$24.11▼$29.5152-Week Range$18.08▼$32.00Volume689,557 shsAverage Volume1.76 million shsMarket Capitalization$3.68 billionP/E RatioN/ADividend YieldN/APrice Target$44.92 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Insmed alerts: Email Address Insmed MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside80.2% Upside$44.92 Price TargetShort InterestBearish6.33% of Shares Sold ShortDividend StrengthN/ASustainability-1.29Upright™ Environmental ScoreNews Sentiment0.51Based on 10 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.68) to ($3.88) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.07 out of 5 starsMedical Sector184th out of 908 stocksPharmaceutical Preparations Industry70th out of 424 stocks 4.5 Analyst's Opinion Consensus RatingInsmed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 12 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageInsmed has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.33% of the outstanding shares of Insmed have been sold short.Short Interest Ratio / Days to CoverInsmed has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in Insmed has recently increased by 3.98%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldInsmed does not currently pay a dividend.Dividend GrowthInsmed does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreInsmed has received a 68.35% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Aminoglycosides", "Preclinical research services for physical health", and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Insmed is -1.29. Previous Next 2.5 News and Social Media Coverage News SentimentInsmed has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.33 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Insmed this week, compared to 3 articles on an average week.Search InterestOnly 13 people have searched for INSM on MarketBeat in the last 30 days. This is a decrease of -7% compared to the previous 30 days.MarketBeat FollowsOnly 9 people have added Insmed to their MarketBeat watchlist in the last 30 days. This is a decrease of -18% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Insmed insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.60% of the stock of Insmed is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Insmed are expected to grow in the coming year, from ($4.68) to ($3.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Insmed is -4.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Insmed is -4.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchMove Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. Here's where Dr. David Eifrig says to move your money immediately. About Insmed Stock (NASDAQ:INSM)Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.Read More INSM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INSM Stock News HeadlinesApril 25, 2024 | investing.comInsmed shares upgraded on growth potentialApril 25, 2024 | prnewswire.comInsmed to Host First-Quarter 2024 Financial Results Conference Call on Thursday, May 9, 2024April 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? April 25, 2024 | americanbankingnews.comInsmed (NASDAQ:INSM) Shares Gap Up to $24.11April 24, 2024 | americanbankingnews.comInsmed (NASDAQ:INSM) Receives New Coverage from Analysts at Truist FinancialApril 24, 2024 | msn.comTruist Securities Initiates Coverage of Insmed (INSM) with Buy RecommendationApril 20, 2024 | msn.comActress Jane Seymour on the Effects of “Unseenism” and the #1 Way To Fight It: “Health Is Everything”April 16, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Insmed (INSM) and UnitedHealth (UNH)April 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? April 16, 2024 | americanbankingnews.comHead to Head Survey: Daré Bioscience (NASDAQ:DARE) versus Insmed (NASDAQ:INSM)April 10, 2024 | finance.yahoo.comWhat Makes Insmed (INSM) a Lucrative Investment?April 6, 2024 | cnn.comInsmed IncorporatedApril 5, 2024 | finanznachrichten.deInsmed Incorporated: Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)March 27, 2024 | finance.yahoo.comInsmed to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International ConferenceMarch 19, 2024 | markets.businessinsider.comStrong Endorsement and Market Expansion Potential Justify Buy Rating for Insmed’s BrensocatibMarch 17, 2024 | finance.yahoo.comINSM Apr 2024 25.000 putMarch 15, 2024 | markets.businessinsider.comCrinetics Pharmaceuticals Earns ‘Buy’ Rating on Clinical Success and Market Expansion PotentialMarch 13, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Insmed (INSM), Oric Pharmaceuticals (ORIC) and CytomX Therapeutics (CTMX)March 12, 2024 | yahoo.comJane Seymour Talks 'Unseenism,' Aging, Advocating for Yourself and MoreMarch 11, 2024 | msn.comJane Seymour Slams Ageism Against Women: ‘It’s a Real, Really Large Issue’March 7, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Insmed (INSM) and Zimmer Biomet Holdings (ZBH)March 1, 2024 | msn.comJane Seymour raises awareness about 'unseenism' after she feels ignored and overlooked as she gets olderMarch 1, 2024 | msn.comJane Seymour Talks About Being ‘Unseen’ as She Ages, Says Men ‘Look Over My Head and Find the Nearest Man’ To Talk ToFebruary 29, 2024 | prnewswire.comInsmed To Present at Three March ConferencesFebruary 28, 2024 | finance.yahoo.comActress Jane Seymour and Insmed Raise Awareness of "Unseenism" and Empower People to Speak Up When It Comes to Their HealthFebruary 28, 2024 | markets.businessinsider.comBuy Rating Affirmed for Insmed on Positive Pipeline Prospects and Robust Revenue ForecastsFebruary 27, 2024 | msn.comUBS Initiates Coverage of Insmed (INSM) with Buy RecommendationSee More Headlines Receive INSM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Insmed and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today4/26/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:INSM CUSIPN/A CIK1104506 Webwww.insmed.com Phone908-977-9900Fax732-438-0381Employees373Year FoundedN/APrice Target and Rating Average Stock Price Target$44.92 High Stock Price Target$55.00 Low Stock Price Target$36.00 Potential Upside/Downside+80.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($5.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-749,570,000.00 Net Margins-245.59% Pretax Margin-244.76% Return on EquityN/A Return on Assets-53.34% Debt Debt-to-Equity RatioN/A Current Ratio4.12 Quick Ratio3.75 Sales & Book Value Annual Sales$305.21 million Price / Sales12.13 Cash FlowN/A Price / Cash FlowN/A Book Value($2.32) per share Price / Book-10.74Miscellaneous Outstanding Shares148,550,000Free Float141,721,000Market Cap$3.70 billion OptionableOptionable Beta0.92 Social Links These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. William H. Lewis J.D. (Age 50)Pres, CEO & Chairman Mr. Paolo Tombesi (Age 55)Chief Financial Officer Ms. Christine A. Pellizzari J.D. (Age 51)Chief Legal Officer & Corp. Sec. Mr. Roger Adsett (Age 50)Chief Commercial Officer Dr. Paul D. Streck (Age 55)Advisor Key CompetitorsPrestige Consumer HealthcareNYSE:PBHAxsome TherapeuticsNASDAQ:AXSMChemoCentryxNASDAQ:CCXIUltragenyx PharmaceuticalNASDAQ:RARECymaBay TherapeuticsNASDAQ:CBAYView All CompetitorsInsiders & InstitutionsWCM Investment Management LLCBought 24,673 shares on 4/25/2024Ownership: 0.215%Assenagon Asset Management S.A.Bought 927,040 shares on 4/24/2024Ownership: 0.816%Rice Hall James & Associates LLCSold 41,938 shares on 4/23/2024Ownership: 0.121%Diversified Trust CoBought 1,078 shares on 4/18/2024Ownership: 0.015%Allspring Global Investments Holdings LLCSold 7,098 shares on 4/18/2024Ownership: 0.003%View All Insider TransactionsView All Institutional Transactions INSM Stock Analysis - Frequently Asked Questions Should I buy or sell Insmed stock right now? 12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last twelve months. There are currently 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" INSM shares. View INSM analyst ratings or view top-rated stocks. What is Insmed's stock price target for 2024? 12 Wall Street research analysts have issued twelve-month price objectives for Insmed's stock. Their INSM share price targets range from $36.00 to $55.00. On average, they anticipate the company's share price to reach $44.92 in the next twelve months. This suggests a possible upside of 80.2% from the stock's current price. View analysts price targets for INSM or view top-rated stocks among Wall Street analysts. How have INSM shares performed in 2024? Insmed's stock was trading at $30.99 at the beginning of 2024. Since then, INSM shares have decreased by 19.6% and is now trading at $24.92. View the best growth stocks for 2024 here. When is Insmed's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our INSM earnings forecast. How can I listen to Insmed's earnings call? Insmed will be holding an earnings conference call on Thursday, May 9th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 609-800-9909 with passcode "7862189". How were Insmed's earnings last quarter? Insmed Incorporated (NASDAQ:INSM) released its quarterly earnings results on Thursday, February, 22nd. The biopharmaceutical company reported ($1.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.13) by $0.15. The biopharmaceutical company had revenue of $83.70 million for the quarter, compared to analysts' expectations of $82.15 million. The business's revenue for the quarter was up 41.1% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.20) EPS. What ETFs hold Insmed's stock? ETFs with the largest weight of Insmed (NASDAQ:INSM) stock in their portfolio include First Trust NYSE Arca Biotechnology Index Fund (FBT), BNY Mellon Innovators ETF (BKIV), Virtus LifeSci Biotech Products ETF (BBP), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Franklin Genomic Advancements ETF (HELX) and Invesco Nasdaq Biotechnology ETF (IBBQ). What guidance has Insmed issued on next quarter's earnings? Insmed updated its FY 2024 earnings guidance on Saturday, February, 24th. The company provided EPS guidance of for the period. The company issued revenue guidance of $340.0 million-$360.0 million, compared to the consensus revenue estimate of $359.5 million. What is Will Lewis' approval rating as Insmed's CEO? 14 employees have rated Insmed Chief Executive Officer Will Lewis on Glassdoor.com. Will Lewis has an approval rating of 78% among the company's employees. What other stocks do shareholders of Insmed own? Based on aggregate information from My MarketBeat watchlists, some companies that other Insmed investors own include Gilead Sciences (gild), AbbVie (ABBV), Johnson & Johnson (JNJ), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA) and Geron (GERN). Who are Insmed's major shareholders? Insmed's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.82%), WCM Investment Management LLC (0.22%), Rice Hall James & Associates LLC (0.12%), Hennion & Walsh Asset Management Inc. (0.10%), Requisite Capital Management LLC (0.02%) and Diversified Trust Co (0.01%). Insiders that own company stock include David R Brennan, John Drayton Wise, Martina MD Flammer, Melvin Md Sharoky, Michael Alexander Smith, Orlov S Nicole Schaeffer, Roger Adsett, Sara Bonstein and William Lewis. View institutional ownership trends. How do I buy shares of Insmed? Shares of INSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:INSM) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryJim Cramer’s “The Biggest Drug Ever”Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insmed Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.